News

Zacks.com on MSN3h
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Novo Nordisk: The Market Has Lost Its Mind
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
sharewise3d
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Indianapolis Business Journal9h
Despite beating expectations, Lilly shares tumble after second-quarter earnings release
Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...
Nasdaq23d
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock? - Nasdaq
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company ...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...